Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
|
Bulevirtide | ||
|
Fostemsavir (Rukobia®) |
As part of triple therapy when supported by MDT |
|
|
Molnupiravir (Lagevrio®) |
For eligible non-hospitalised patients (12 years and over) oral antiviral medicines are provided, following assessment, by Badger Covid Medicines Delivery Unit (CMDU), in line with NICE Technology Appraisal 878 and 1056. COVID-19 community treatment pathway, including eligibility criteria, treatment options and information on referral to Badger CMDU. NICE Technology Appraisal 1056: Molnupiravir for treating COVID-19 |
|
|
Nirmatrelvir plus ritonavir (Paxlovid®) | ||
|
Symtuza® |